David Young
Dr Young joined AGI in June 2006 from the GloboMax Division of ICON plc where he was executive vice president with responsibility for strategic drug development efforts in the US. Founded by Dr Young in 1997, GloboMax was acquired in 2003 by ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.
Prior to forming GloboMax, Dr Young had a distinguished career in academia. He was with the University of Maryland at Baltimore for 11 years where he was a tenured associate professor in the Department of Pharmaceutical Sciences and the managing director of the Clinical Research Unit. During this period the US Food and Drug Administration (FDA) placed major research and education programmes with the university, providing Dr Young with opportunities to work closely with and train FDA staff on various regulatory science topics, including his collaborating with FDA on establishing various FDA Guidances.
During his career, Dr Young has worked on over 50 new drug applications (NDAs) to the FDA, many based on the 505(b)(2) NDA process, including therapeutic indication switches
and drug delivery reformulations of known molecular entities,
five of which were specifically for products in the gastro-enterology field.
